You are here: Industry Insights > HiFiBiO Therapeutics

News List

HiFiBiO completes first cohort of phase 1 study of SARS-CoV-2 neutralising antibody pharmaceutical-business-review
October 29, 2020
HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment and prevention of COVID-19.
HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19 pharmaceutical-business-review
September 17, 2020
HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.
Kite, HiFiBiO Therapeutics partner to discover novel targets and antibodies against AML pharmaceutical-business-review
September 08, 2020
Kite, a Gilead Company and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML).
HiFiBiO Therapeutics Closes $67 M Series C Financing biospectrumasia
September 04, 2019
The firm will now Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders
HiFiBiO Therapeutics Signs Multi-Target Antibody Discovery Agreement with Takeda pharmafocusasia
November 27, 2018
HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced...